We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+48.62%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$958M
AUM Growth
+$204M
Cap. Flow
+$76.9M
Cap. Flow %
8.03%
Top 10 Hldgs %
62.37%
Holding
42
New
13
Increased
9
Reduced
9
Closed
3

Top Buys

Rank Stock Value
1
ACHN
Achillion Pharmaceuticals
ACHN
+$48M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$32.9M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$29.6M
4
PRTA icon
Prothena Corp
PRTA
+$20.3M
5
BLUE
bluebird bio
BLUE
+$13.4M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$94M
2
KERX
Keryx Biopharmaceuticals Inc
KERX
+$29.1M
3
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$19.4M
4
OMER icon
Omeros
OMER
+$11.3M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 63.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
26
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$9.39M 0.98%
+55,556
New +$8.94M
ENZ
27
DELISTED
Enzo Biochem, Inc.
ENZ
$8.44M 0.88%
3,348,029
– –
MRTX
28
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.36M 0.87%
+551,723
New +$5.42M
DVAX
29
DELISTED
Dynavax Technologies
DVAX
$7.14M 0.75%
600,000
– –
ACHV icon
30
Achieve Life Sciences
ACHV
$633M
$7.08M 0.74%
347
-45
-11% -$932K
FBIO icon
31
CALL
Fortress Biotech
FBIO
$111M
$7.01M 0.73%
+66,667
New +$8.17M
PTCT icon
32
PTC Therapeutics
PTCT
$6.18B
$6.44M 0.67%
+300,000
New +$5.21M
ARWR icon
33
Arrowhead Research
ARWR
$12.1B
$5M 0.52%
879,561
-2,235,194
-72% -$8.59M
DYAX
34
CALL
DELISTED
DYAX CORPORATION
DYAX
$3.43M 0.36%
+500,000
New +$2.27M
TGTX icon
35
TG Therapeutics
TGTX
$8.19B
$3.02M 0.32%
+600,000
New +$3.67M
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.08B
$1.96M 0.2%
+70,000
New +$1.93M
OCRX
37
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.83M 0.19%
215,999
-9,001
-4% -$72.6K
EPZM
38
DELISTED
Epizyme, Inc
EPZM
$400K 0.04%
10,000
-141,000
-93% -$4.77M
ENTA icon
39
Enanta Pharmaceuticals
ENTA
$362M
– –
-436,145
Closed -$7.72M
SNMX
40
DELISTED
Senomyx, Inc.
SNMX
– –
-975,610
Closed -$2.13M
RCPT
41
DELISTED
RECEPTOS INC COM STK (DE)
RCPT
– –
-975,000
Closed -$19.4M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2013 Portfolio in Review

As of Q3 2013, RA Capital Management held 42 positions worth $958M, up 27% from $754M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

RA Capital Management deployed $76.9M of net new capital in Q3 2013, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was ChemoCentryx, Inc.: 3,045,380 shares worth $16.9M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 71% a quarter earlier.

On the sell side, the largest reduction was Acadia Pharmaceuticals, an estimated $94M trimmed.

  • RA Capital Management's largest Q3 2013 buy was ChemoCentryx, Inc.: 3,045,380 shares worth $16.9M.
  • RA Capital Management added most to Achillion Pharmaceuticals in Q3 2013, an estimated $48M increase.
  • RA Capital Management's biggest Q3 2013 reduction was Acadia Pharmaceuticals, cutting an estimated $94M.
  • RA Capital Management fully exited RECEPTOS INC COM STK (DE) in Q3 2013, selling an estimated $19.4M.
  • RA Capital Management's ten largest holdings make up 62% of its $958M portfolio in Q3 2013.
  • RA Capital Management opened 13 new positions and closed 3 in Q3 2013.
  • RA Capital Management's portfolio value rose 27% quarter-over-quarter to $958M.

Based on RA Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.